Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic.
10.1007/s11684-022-0930-5
- Author:
Chuansong QUAN
1
,
2
;
Zhenjie ZHANG
1
,
2
;
Guoyong DING
3
,
4
;
Fengwei SUN
5
;
Hengxia ZHAO
6
;
Qinghua LIU
7
;
Chuanmin MA
1
,
2
;
Jing WANG
1
,
2
;
Liang WANG
1
,
2
;
Wenbo ZHAO
1
,
2
;
Jinjie HE
6
;
Yu WANG
8
;
Qian HE
3
,
4
;
Michael J CARR
9
;
Dayan WANG
10
;
Qiang XIAO
11
;
Weifeng SHI
1
,
12
Author Information
1. Key Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University &
2. Shandong Academy of Medical Sciences, Taian, 271000, China.
3. School of Public Health, Shandong First Medical University &
4. Shandong Academy of Medical Sciences, Jinan, 250117, China.
5. The Department of Infectious Disease, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, China.
6. Clinical Laboratory, The Department of Clinical Laboratory, Boshan District Hospital, Zibo, 255200, China.
7. Clinical Laboratory, The Department of Clinical Laboratory, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, China.
8. The Department of Cancer Center, Taian Tumor Prevention and Treatment Hospital, Taian, 271000, China.
9. National Virus Reference Laboratory, School of Medicine, University College Dublin, Dublin 4, Ireland.
10. Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Collaboration Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention, Key Laboratory for Medical Virology, National Health and Family Planning Commission, Beijing, 102206, China.
11. Clinical Laboratory, The Department of Clinical Laboratory, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, China. tyfy8011@126.com.
12. Shandong Academy of Medical Sciences, Taian, 271000, China. shiwf@ioz.ac.cn.
- Publication Type:Journal Article
- Keywords:
COVID-19;
antibody;
cross-sectional study;
influenza virus;
seroprevalence
- From:
Frontiers of Medicine
2022;():1-7
- CountryChina
- Language:English
-
Abstract:
Nonpharmaceutical interventions (NPIs) have been commonly deployed to prevent and control the spread of the coronavirus disease 2019 (COVID-19), resulting in a worldwide decline in influenza prevalence. However, the influenza risk in China warrants cautious assessment. We conducted a cross-sectional, seroepidemiological study in Shandong Province, Northern China in mid-2021. Hemagglutination inhibition was performed to test antibodies against four influenza vaccine strains. A combination of descriptive and meta-analyses was adopted to compare the seroprevalence of influenza antibodies before and during the COVID-19 pandemic. The overall seroprevalence values against A/H1N1pdm09, A/H3N2, B/Victoria, and B/Yamagata were 17.8% (95% CI 16.2%-19.5%), 23.5% (95% CI 21.7%-25.4%), 7.6% (95% CI 6.6%-8.7%), and 15.0 (95% CI 13.5%-16.5%), respectively, in the study period. The overall vaccination rate was extremely low (2.6%). Our results revealed that antibody titers in vaccinated participants were significantly higher than those in unvaccinated individuals (P < 0.001). Notably, the meta-analysis showed that antibodies against A/H1N1pdm09 and A/H3N2 were significantly low in adults after the COVID-19 pandemic (P < 0.01). Increasing vaccination rates and maintaining NPIs are recommended to prevent an elevated influenza risk in China.
